Agios Q4: PYRUKYND revenue $10.7M, mitapivat PDUFA Sept 7, 2025; cash $1.5B

AGIOS PHARMACEUTICALS, INC.

2024-FY EPS reported $11.64 revenue$36,498,000

PYRUKYND net revenue $10.7M in Q4 (+20% QoQ), full year $36.5M vs $26.8M in 2023.
Filed for mitapivat approval in thalassemia in US, EU, KSA, UAE; PDUFA goal date Sept 7, 2025.
Phase 3 RISE UP for sickle cell disease fully enrolled (>200 patients); topline results late 2025, potential launch 2026.
Cash, cash equivalents and marketable securities $1.5B as of Dec 31, 2024; net loss Q4 $96.5M, full year net income $673.7M.
Board member David Schenkein to step down effective Feb 28, 2025; remains as strategic advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.